赛治治疗甲亢致粒细胞缺乏症治疗体会  

Therapy Experience of Agranulocytosis Caused by Thyrozol Treatment on Hyperthyroidism

作　　者：郑彩娥[1] 何凌[1] 尹龙燕[1] 李颖能[1] 王燕[1] 

机构地区：[1]广州市第一人民医院职工保健室,广东广州510180

出　　处：《临床医学工程》2011年第1期93-94,共2页Clinical Medicine & Engineering

摘　　要：目的总结抗甲状腺药物赛治治疗甲亢致粒细胞缺乏症(粒缺)的临床特点及治疗措施。方法回顾性分析我院2009-01-01至2010-06-10收治的14例赛治治疗甲亢致粒缺患者的临床资料。结果 10例在服药后1个月发生粒缺,4例在2个月发生粒缺。粒细胞在停用赛治4周内恢复8例,停用赛治8周内恢复6例,无死亡病例。结论粒细胞缺乏症为抗甲亢药物少见但非常严重的不良反应,不可预测,在甲亢开始治疗2个月内定期复查血常规,高度警惕粒缺的发生。Objective To summarize the clinical characters and therapy methods of agranulocytosis caused by thyrozol treatment on hyperthyroidism.Methods Retrospectively analyzing the clinical data of 14 patients who were admitted to our hospital because of agranulocytosis caused by thyrozol treatment on hyperthyroidism from 01-Jan-2009 to 10-Jun-2010.Results Agranulocytosis occurred in ten patients in one month after thyrozol therapy and in four patients in two months.Granulocyte amount returned to normal level in 8 patients in 4 weeks after stopping using thyrozol and 6 patients in 8 weeks.No patient died of agranulocytosis.Conclusions Agranulocytosis is an uncommon but severe and unpredictable adverse effect of anti-hyperthyroidism drugs.We must monitor blood routine regularly in the first two months of hyperthyroidism treatment to decrease the incidence of agranulocytosis.

关 键 词：赛治 粒细胞缺乏症 

分 类 号：R557.3[医药卫生—血液循环系统疾病]